Theratechnologies (THTX) said Thursday that Future Pak affiliate CB Biotechnology has finalized its acquisition of the company for $3.01 per share in cash plus one contingent value right per share.
The company's shares are set to be delisted from Nasdaq on or about Thursday and from the Toronto Stock Exchange on or about Friday, the company said.
The contingent value right is of up to $1.19 per share if specific milestones are achieved by Theratechnologies, the company said.
Shares were down 0.7% in recent afternoon trading.
Price: 3.37, Change: -0.02, Percent Change: -0.74
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments